Kymera Therapeutics Inc (KYMR)

NASDAQ
58.15
+0.77(+1.34%)
  • Volume:
    246,430
  • Bid/Ask:
    45.60/58.15
  • Day's Range:
    55.58 - 58.32

KYMR Overview

Prev. Close
57.38
Day's Range
55.58-58.32
Revenue
52.74M
Open
57.72
52 wk Range
25.43-91.92
EPS
-
Volume
246,430
Market Cap
2.62B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
-
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
45,030,094
Next Earnings Date
Nov 04, 2021
What is your sentiment on Kymera Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Kymera Therapeutics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Kymera Therapeutics Inc Company Profile

Kymera Therapeutics Inc Company Profile

Employees
92

Kymera Therapeutics Inc is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation platform, Pegasus, allows it to discover selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. Its initial programs include IRAK4, IRAKIMiD, and STAT3. The Company is developing its IRAK4 program for the treatment of a broad set of immunology-inflammation diseases, including hidradenitis suppurativa (HS), atopic dermatitis (AD) and rheumatoid. Its programs are focused on a single critical signaling node within the genetically and clinically validated IL-1R/TLR and JAK/STAT pathways.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.